Validea Detailed Fundamental Analysis

Validea's Multi-Factor Investor model, based on Pim van Vliet's low volatility, strong momentum, and high net payout yield strategy, identified ELEVANCE HEALTH INC (ELV) as its top performer among 22 guru strategies. However, ELV's 75% rating falls below the 80% threshold for 'some interest,' and the stock ultimately received a 'FAIL' on the strategy's final rank, indicating it does not fully satisfy the model's investment criteria despite passing market cap and standard deviation tests.

Analysis

Elevance Health (ELV) has been identified as a top-ranking security under Validea's Multi-Factor Investor model, which is based on Pim van Vliet's strategy favoring low volatility, strong momentum, and high net payout yields. Despite this high relative ranking among 22 strategies, ELV ultimately receives a 'FAIL' on the model's final assessment. The stock's score of 75% falls below the 80% threshold that indicates strategic interest. The analysis reveals a mixed performance against the model's core criteria: while ELV, a large-cap growth stock, successfully passes tests for market capitalization and low volatility (Standard Deviation: PASS), it shows weakness in other key areas. Specifically, its 'Twelve Minus One Momentum' and 'Net Payout Yield' are both rated as 'NEUTRAL'. This indicates that while the stock exhibits desirable conservative characteristics, its recent performance momentum and shareholder return profile are not sufficiently strong to meet the stringent requirements of this particular quantitative strategy, leading to the disqualifying final rank.

Key Decisions for Investors

• Investors strictly adhering to Pim van Vliet's multi-factor strategy should note that ELV does not currently qualify for inclusion, as its neutral momentum and net payout yield result in a 'FAIL' rating.
• For conservative investors, ELV's confirmed low-volatility profile is a positive attribute, but the neutral ratings on momentum and yield warrant caution and suggest monitoring for improvement in these factors before building a position.
• Given the stock fails this specific quantitative screen, it is prudent to weigh this outcome against broader fundamental research and other factor models that may place different weights on volatility, value, or growth characteristics.